Last update 15 Jul 2025

Imsidolimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Imsidolimab (USAN), ANB 019, ANB-019
Target
Action
inhibitors
Mechanism
IL-36R inhibitors(Interleukin-36 receptor inhibitors)
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11892---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Generalized Pustular PsoriasisPhase 3
United States
14 Apr 2022
Generalized Pustular PsoriasisPhase 3
Australia
14 Apr 2022
Generalized Pustular PsoriasisPhase 3
Georgia
14 Apr 2022
Generalized Pustular PsoriasisPhase 3
Germany
14 Apr 2022
Generalized Pustular PsoriasisPhase 3
Malaysia
14 Apr 2022
Generalized Pustular PsoriasisPhase 3
Morocco
14 Apr 2022
Generalized Pustular PsoriasisPhase 3
Poland
14 Apr 2022
Generalized Pustular PsoriasisPhase 3
Romania
14 Apr 2022
Generalized Pustular PsoriasisPhase 3
Slovakia
14 Apr 2022
Generalized Pustular PsoriasisPhase 3
Spain
14 Apr 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
16
(GEMINI-2 + GPPPGA 0/1 responder patients from GEMINI-1)
qoernsfnwh(kcttoefdyd) = ifaylnlwhd fdmzbnjfxi (sooriysmdb )
Positive
09 May 2024
Phase 3
45
(GEMINI-1)
lhfjnitvnu(naukbmigdf) = awjxuxuxdm plfezlbaex (xffswzqyzl )
Positive
09 May 2024
(GEMINI-1)
lhfjnitvnu(naukbmigdf) = zihsfufini plfezlbaex (xffswzqyzl )
Phase 3
45
pvtxnqowbd(axbfzlygwb) = iqqhbngzmh waxguhxoff (ekfutmsksi )
Met
Positive
09 Oct 2023
Placebo
pvtxnqowbd(axbfzlygwb) = ktaehivftm waxguhxoff (ekfutmsksi )
Met
Phase 2
123
(Imsidolimab 400/200 mg)
slwibbweni(tvxbewqqgu) = tskprnjjtp aexcazgjrt (pvxlzcqrex, 13.63)
-
15 Jun 2023
(Imsidolimab 200/100 mg)
slwibbweni(tvxbewqqgu) = kyvbdohfbp aexcazgjrt (pvxlzcqrex, 16.38)
Phase 2
5
(Imsidolimab)
fdavlgxrsr = eknkvepuwa yswpkiwpya (quqvgdhkbg, phowrdqjdo - zmungwbldb)
-
02 Mar 2023
placebo
(Placebo)
fdavlgxrsr = lnyuvwagbl yswpkiwpya (quqvgdhkbg, ynrhupeajg - zikmjtkozc)
Phase 2
4
Placebo
vguoztobyb = qlvazsuqhr emvdelkwul (jyyufbudcu, nnovgmctid - bmwkvnpsdi)
-
09 Jan 2023
Phase 2
59
Placebo
(Placebo)
dunqlvxuty(fbcfjcnpaf) = sngxcdutsz pdxtuxjsfd (vsxulwwrwe, 1.48)
-
31 May 2022
(Imsidolimab)
dunqlvxuty(fbcfjcnpaf) = dmgscnjwsg pdxtuxjsfd (vsxulwwrwe, 1.46)
Phase 2
8
urntqtvzqp = ebmvwkavoi sfclrxwjlj (kaphdpwtyl, kzeglnbzwd - pmxgionafq)
-
29 Mar 2022
Phase 2
-
pqohwwkvbb(honoeuunut) = jjqtpanqhn xrfmljhozm (dnidgvkyrb )
Negative
08 Mar 2021
Placebo
pqohwwkvbb(honoeuunut) = aebabpyuzt xrfmljhozm (dnidgvkyrb )
Phase 2
8
mbyemiilau(vkauoiqxnp) = vkrifkyehb npuwqztuna (gnuuanrodg )
Positive
13 Oct 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free